Day: March 1, 2024

CAVE CREEK, AZ, March 01, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Endexx Corporation (OTCQB: EDXC), a pioneer in the plant-based wellness sector, today disclosed a pivotal update to its corporate governance framework. Following a comprehensive review and in alignment with our strategic vision for growth and transparency, Endexx has made the decisive move to engage Victor Mokuolu, CPA PLLC (VMCPA) as our new independent auditor, effective from the fiscal year ended September 30, 2023. This transition is detailed in our recent Form 8-K/A filing with the Securities and Exchange Commission. The decision to part ways with our previous auditors, Turner, Stone & Company, L.L.P. (T&S), was ratified by our Board of Directors on February 9, 2024. It’s imperative to note that this change was necessitated by a series of...

JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following industry events during the month of March 2024. BIO-Europe Spring®CCIB Barcelona, SpainMarch 18 – 20, 2024 Future Food-tech – Innovation & Investment from Farm to ForkSan Francisco Marriott Marquis, CaliforniaMarch 21 – 22, 2024Booth #27 Vaccine Innovation Forum WorldChina Grain Hotel, Shanghai, ChinaMarch...

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives. This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors.  SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the...

Comscore to provide currency-grade measurement metrics for TEGNA’s multi-platform media businesses RESTON, Va., March 01, 2024 (GLOBE NEWSWIRE) — Comscore, Inc. (NASDAQ: SCOR) and TEGNA Inc. (NYSE: TGNA) today announced they have reached a comprehensive multi-year agreement on cross-platform audience measurement. Under the terms of the agreement, Comscore will extend its relationship with TEGNA as a key measurement partner in all TEGNA markets, providing it with critical measurement metrics across its local TV, major affiliate, and digital businesses.  TEGNA owns 64 local news brands in 51 markets, making it one of the largest and geographically diverse broadcasters in the U.S. It is the largest owner of Big Four affiliates in the top 25 markets among independent station groups and reaches approximately 39 percent of all TV households...

– All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met – – Complete remission (CR) achieved after three months of treatment with duration of eight months and one year survival at the latest assessment – – First time achievement of CR with CDK9 inhibition monotherapy in relapsed/refractory (r/r) acute myeloid leukemia (AML) patient – – Phase 2a data in r/r AML patients expected in March and Q2 2024 – NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the delivery of an oral presentation of data for the cohort of patients...

Aktia Bank PlcStock Exchange Release1 March 2024 at 3.00 p.m. Changes in the number of own shares held by Aktia Bank Plc Aktia Bank Plc has today, based on a decision made by the company’s Board of Directors, divested a total of 133,147 own shares held by the company to approximately 500 persons. The shares have been divested in accordance with the terms of the share-based incentive scheme AktiaUna and as a part of the Company’s short-term and long-term renumeration programs to certain key persons. The share-based incentive scheme AktiaUna is directed to all Aktia employees and the divestment pertains to the earning period 2022–2023. The divestment of own shares is based on the authorisations by the Annual General Meeting of Shareholders held on 5 April 2023. After the above-mentioned divestment, a total of 121,608 shares remain...

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:Morgan Stanley Technology, Media and Telecom Conference – March 4-7, 2024 KeyBanc Emerging Technology Summit – March 5-6, 2024 Leerink Partners Global Biopharma Conference – March 11-13, 2024 KeyBanc Life Sciences & MedTech Investor Forum – March 19-20, 2024About Recursion Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets....

Company Announcement Copenhagen, 1 March 2024 No. 6/2024 ISS A/S, a leading workplace experience and facility management company, discloses the data of the transaction(s) made in ISS shares by the company’s board members, executives (“PDMRs”) and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. With reference to the long-term incentive programme (LTIP) from 2021, the following Performance Share Units (“PSUs”) have vested, and a corresponding number of ISS shares have been delivered on 1 March 2024 to the PDMRs listed below:Name Type Units New share holdingKasper Fangel, Group CEO PSUs 19,631 42,946.73Rune Christensen, Employee elected Board member PSUs 2,100 4,505Subsequently, Rune Christensen, Employee elected Board member, has...